Investing in Turkey’s pharmaceutical sector means stepping into a highly regulated, but strategically positioned market that serves as a bridge between Europe, the Middle East and Central Asia. For foreign investors, Turkey combines a liberal foreign investment regime with a mature regulatory framework for medicines, a strong generics base and ambitions to become a regional hub for pharmaceutical production and export.
This brief is designed as a lawyer’s roadmap: it focuses less on market hype and more on the hard legal infrastructure you must navigate—licensing, GMP, pricing, reimbursement, promotion and deal structure.
1. The legal architecture: who regulates what?
Turkey’s pharmaceutical sector is built on several pillars of legislation and institutions:
- Pharmaceutical and Medical Preparations Law No. 1262 – the foundational statute for medicinal products.
- The Regulation on the Licensing of Human Medicinal Products, most recently updated in line with EU law (effective 11 December 2021), which sets out the procedures for marketing authorisation.
- The Turkish Medicines and Medical Devices Agency (TITCK), under the Ministry of Health, which handles marketing authorisations, GMP inspections, pharmacovigilance and promotion oversight.
- The Social Security Institution (SGK), which decides on reimbursement and effectively shapes market access and pricing outcomes.
- The Foreign Direct Investment Law No. 4875, which guarantees equal treatment for foreign investors, including those in the pharmaceutical sector.
For an investor, the key insight is that corporate law and FDI rules are investor-friendly, but product regulation and pricing are tight and technical.
2. Foreign investment and market entry options
Turkey’s foreign investment regime is simple at its core:
- Foreign and domestic investors must be treated equally, unless a specific law provides otherwise.
- Foreign investors are free to incorporate companies or acquire shares in existing Turkish entities.
- There is generally a notification requirement after the investment, not a prior authorisation system.
Based on this, foreign investors usually enter Turkey’s pharmaceutical sector through one (or a combination) of the following models:
- Greenfield manufacturing or marketing company
- Incorporation of a Turkish joint stock or limited liability company.
- Subsequent application for facilities licences, GMP and product marketing authorisations.
- Acquiring an existing Turkish pharmaceutical or distribution company
- Share purchase brings immediate access to local licences, registrations and networks, but also to legacy liabilities (regulatory, tax, compliance).
- Licensing and distribution partnerships
- A foreign MA holder grants a Turkish company rights to register, import, distribute and promote products.
- The Turkish partner often becomes the local marketing authorisation holder, facing the Agency directly.
- Contract manufacturing / toll manufacturing
- Using Turkish GMP-compliant plants to manufacture for the domestic market and export.
Each option carries different levels of regulatory responsibility, capital commitment and exposure to Turkey-specific pricing and reimbursement rules.
3. Marketing authorisation and GMP: the price of admission
Under Law No. 1262 and the Licensing Regulation, no medicinal product for human use may be placed on the Turkish market without a valid marketing authorisation issued by TITCK.
Key elements:
- Dossier requirements – similar to EU CTD structures, including quality, safety and efficacy data.
- GMP certification – TITCK requires a valid GMP certificate for the manufacturing site; for most imported products, an EU GMP certificate alone is not enough, and TITCK may inspect foreign plants itself.
- Timelines – the Licensing Regulation targets completion of the marketing authorisation procedure within 210 days, but in practice, studies show that total approval times often range between 18–24 months, especially when GMP inspections are involved.
- Renewals – marketing authorisations are subject to periodic renewal (e.g. every five years), with ongoing pharmacovigilance and quality obligations.
For investors, this means:
- Your go-to-market timeline is measured in years, not months.
- GMP compliance and regulatory affairs expertise are not optional extras—they are deal-critical capabilities.
4. Pricing and reimbursement: where value is really decided
Even a perfectly licensed medicine may be commercially unviable if pricing and reimbursement fail.
The Turkish pricing and reimbursement system rests on three main pillars:
- Reference pricing
- Ex-factory prices are set by reference to a basket of EU countries, applying a specific currency conversion system.
- Marketing authorisation price approval
- After licensing, the company applies for a price to be approved by TITCK, following detailed rules and caps specific to product type and status.
- SGK reimbursement decision
- To access the bulk of the market, companies apply to SGK to have products listed for reimbursement.
- Applications are reviewed clinically, technically and economically; pricing and discount terms (iskonto) are set by the Social Security Institution based on evaluations by specialised committees.
Recent developments also include alternative reimbursement models, where a Price Evaluation Commission may adopt differentiated pricing, outcome-based arrangements or special margins for certain products outside standard rules.
For investors, this makes clear that:
- Regulatory risk is not limited to licensing; pricing and reimbursement decisions can severely compress margins.
- Any valuation of a Turkish pharma asset must critically assess its SGK listing status, discount levels and probability of price revisions over time.
5. Promotion, compliance and ethics
Turkey has strict rules on promotion of medicinal products, especially prescription medicines:
- Advertising of medicinal products is regulated under Law No. 1262 and the Regulation on Promotion Activities of Medicinal Products for Human Use.
- Direct-to-consumer advertising for prescription drugs is prohibited; promotion is largely restricted to healthcare professionals.
- Industry associations (such as AIFD) maintain detailed codes of promotional practice consistent with international standards.
In addition, companies must comply with:
- Pharmacovigilance requirements (signal detection, risk management plans, reporting obligations);
- Anti-corruption and hospitality limits in HCP interactions;
- Data protection law (KVKK) when handling patient, HCP or trial subject data.
For foreign investors acquiring or partnering with Turkish companies, compliance culture is a central due diligence theme: legacy promotional or PV breaches can lead to administrative fines, suspension of activities or reputational damage.
6. Transaction structures and due diligence red flags
When investing in Turkey’s pharmaceutical sector through M&A or joint ventures, you should tailor your due diligence and transaction documents to regulatory realities:
6.1. Regulatory and IP due diligence
- Confirm the status of all marketing authorisations: validity, renewals, variations, pharmacovigilance inspections.
- Check that manufacturing sites (in Turkey or abroad) hold valid GMP certificates recognised by TITCK.
- Verify that trademarks, patents, data exclusivity and know-how are properly owned or licensed to the target.
6.2. Market access and economic profile
- Review SGK reimbursement status and discount obligations product by product.
- Analyse exposure to reference price cuts, currency movements and alternative reimbursement schemes.
6.3. Corporate and FDI aspects
- Confirm corporate structure, share capital and compliance with the FDI regime (including past notifications).
- In heavily regulated sub-sectors (e.g. certain biologicals, blood products), check whether any special approvals are attached to shareholding thresholds.
These findings should translate directly into representations, warranties, indemnities and closing conditions in your SPA or JV agreement.
7. A practical roadmap for foreign investors
To make this brief operational, a foreign investor considering a move into Turkey’s pharmaceutical sector should roughly follow this sequence:
- Define your strategy
- Are you seeking manufacturing capacity, portfolio localisation, regional hub status, or all three?
- Choose between greenfield, acquisition, licensing or hybrid structures.
- Map the regulatory path
- Identify which products you want to bring to Turkey and their regulatory status elsewhere.
- Estimate realistic timeframes for marketing authorisation and GMP approvals.
- Model pricing and reimbursement exposure
- Build scenarios for reference price evolution, SGK discounts and potential alternative reimbursement pathways.
- Assess partners and targets
- Conduct deep due diligence on potential Turkish partners or targets—regulatory, compliance, tax and corporate.
- Evaluate their relationships with regulators and payers, but avoid over-reliance on personal networks instead of robust compliance.
- Structure the deal
- Align governing law, dispute resolution, conditions precedent and covenants with Turkish law realities.
- In acquisitions, consider earn-outs or price adjustments tied to regulatory milestones (e.g. SGK listing, tender wins).
- Build compliance into the business plan
- Budget for regulatory affairs, pharmacovigilance, quality and compliance staff; these are not purely “overhead” but part of the license to operate.
Handled in this way, investing in Turkey’s pharmaceutical sector can offer foreign investors not only access to a sizeable domestic market, but also a platform jurisdiction for regional production and distribution—grounded firmly in a legal framework that, while demanding, is increasingly aligned with European standards.
Yanıt yok